T2 Biosystems Inc
NASDAQ:TTOO
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Vaibhav Global Ltd
NSE:VAIBHAVGBL
|
IN |
EV/EBIT
Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBIT returns to its Industry Average (14.3), the stock would be worth $-0.18 (6 092% downside from current price).
| Scenario | EV/EBIT Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | -0.2 | $0 |
0%
|
| Industry Average | 14.3 | $-0.18 |
-6 092%
|
| Country Average | 19.6 | $-0.25 |
-8 337%
|
Forward EV/EBIT
Today’s price vs future ebit
Peer Comparison
| Market Cap | EV/EBIT | P/E | ||||
|---|---|---|---|---|---|---|
| US |
|
T2 Biosystems Inc
NASDAQ:TTOO
|
84.2k USD | -0.2 | -0 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | -192 227.3 | -160 127.7 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
362.6B USD | 19.6 | 84.7 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
185.9B USD | 14 | 24.2 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
165.4B USD | 15 | 19.4 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | -565.5 | -533.6 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
110.9B USD | 22 | 28.1 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
79B USD | 14.8 | 17.5 | |
| NL |
|
argenx SE
XBRU:ARGX
|
42B EUR | 41.9 | 38 | |
| AU |
|
CSL Ltd
ASX:CSL
|
66.1B AUD | 13.1 | 30.7 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | -60.1 | -61.8 |
Market Distribution
| Min | 0 |
| 30th Percentile | 13.6 |
| Median | 19.6 |
| 70th Percentile | 27.8 |
| Max | 1 826 183.2 |
Other Multiples
T2 Biosystems Inc
Glance View
T2 Biosystems, Inc. engages in the development of a proprietary technology platform. The company is headquartered in Lexington, Massachusetts and currently employs 182 full-time employees. The company went IPO on 2014-08-07. The firm is focused on rapid detection of sepsis-causing pathogens and antibiotic resistance genes. The firm is using its T2MR technology, which enables rapid detection of pathogens, biomarkers and other abnormalities in a variety of unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum and urine, and can detect cellular targets at limits of detection as low as one colony forming unit per milliliter (CFU/mL). Its products include the T2Dx Instrument, T2Candida Panel, the T2Bacteria Panel, the T2Resistance Panel, and the T2SARS-CoV-2 Panel that are all powered by the T2MR technology. Its T2Candida Panel is a direct-from-blood test that identifies the lethal form of common blood stream infections that cause sepsis and candidemia. Its T2Bacteria Panel is a direct-from-blood test that detects certain bacterial pathogens associated with sepsis.
